Skip to Main Content

Paper Details

An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.
JCI Insight
31
2019
B16, B16 cells, CD25, CD8+ T cells, IFN, IL-2R chain, T cell, T cells, WT, cancer, gp100, metastatic cancers, mice, mouse, mutated gp100 epitopes, mutation-reactive CD8+ T cells, patients, pmel, pmel-1, pmel-1 T cell receptor, pmel-1 T cells, pmel-1-specific T cells, tumor, vascularized tumor
Author NameAffiliation
Zhiya YuNational Cancer Institute (NCI)
Zhiya YuCenter for Cell-Based Therapy
Zhiya YuNational Cancer Institute (NCI)
Zhiya YuCenter for Cell-Based Therapy
Nicholas P RestifoNational Cancer Institute (NCI)
Nicholas P RestifoCenter for Cell-Based Therapy
Nicholas P RestifoCenter for Cell-Based Therapy
Nicholas P RestifoNational Cancer Institute (NCI)
  • 1 - 8

Datasets

Release 1.2